diffusion [
]. The patient's father signed the written informed consent.
Based on the clinicoradiologic findings, a provisional diagnosis of brainstem glioma was made. The patient underwent retromastoid craniotomy and tumor resection. The tumor was soft to firm in consistency, grayish-white in color, with mild-to-moderate vascularity.
Postoperatively, a very tiny specimen was sent for histopathological examination and was subjected to squash smears preparation that showed features of low-grade glioma. Afterward, the specimen received in formalin for paraffin sections was stained with hematoxylin and eosin, which revealed a cellular tumor composed of medium-sized cells in diffuse sheets, having round nuclei, granular chromatin, conspicuous nucleoli, and scant cytoplasm [ Figure 2 ]. At places, perinuclear clearing along with microvascular and endothelial cell proliferation and small areas of necrosis was seen. Mitosis was 0-1/high-power field [ Figure 2 ]. On routine histopathology, all features were consistent with the diagnosis of glioblastoma.
Since WHO 2016 classification, [2] clearly defines a separate entity of diffuse midline glioma, we evaluated the tumor for the presence of the H3K27M-mutation. Immunohistochemical staining showed that the tumor cells were positive for glial fibrillary acidic protein, retained alpha thalassemia/mental retardation syndrome X-linked, and showed immunopositivity for isocitrate dehydrogenase-1 (IDH-1) mutation and immunonegativity for p53. More importantly, there was a strong immunopositivity for H3-K27M mutation [ Figure 2 ]. The diagnosis of a diffuse midline glioma with H3-K27M mutation was made in accordance with the WHO Classification of Tumors of the Central Nervous System, 4 th edition. In spite of the best postoperative care, the patient died 2 weeks postoperatively.
disCussion
In the pediatric population, diffuse midline glioma arises from the pons (about 50%), thalamus (13%), cerebellum (5%), and spinal cord (3%). [3] According to the WHO Classification of Tumors of the Central Nervous System, 4 th edition, [2] the median age of presentation of diffuse midline glioma is 5-11 years with the pontine tumors developing earlier (7 years) than the thalamic tumors (11 years) . There is no sex difference.
Solomon et al. [1] and Aboian et al. [4] analyzed the data of 47 and 24 cases in their studies of diffuse midline glioma for histone H3-K27M-mutation, respectively. Solomon et al. found that the age at diagnosis ranged from 2 to 65 years (median 14 years) and concluded pontine tumors (median age 7 years) develop at an earlier age than thalamic (24 years) and spinal cord (25 years) tumors. The incidence with respect to location and age of these tumors is summarized in Table 1 and Figure 3 . [1] The clinical presentation depends mainly on the location of the tumor, but the classic clinical presentation is the triad of multiple cranial neuropathies, long tract signs, and ataxia. The history is usually short and includes nausea, vomiting, drowsiness, up-beating nystagmus, or facial numbness. On MRI, these tumors are usually T1 hypointense and T2 hyperintense. These tumors can show contrast enhancement, necrosis, and/or hemorrhage. In 2017, Aboian et al. [4] reviewed imaging characteristics of these tumors in pediatric patients [ Table 2 ]. They also tried to compare the imaging characteristics of H3-K27M mutant to wild-type tumor. For posterior fossa tumors, they found no significant difference [1] and Aboian et al. [4] and for thalamus location due to a lesser number of cases, the comparison was limited.
Tumors harboring H3-K27M mutation show wide morphological variations including small monomorphic cells, giant cells, epithelioid cells, primitive neuroectodermal tumor-like tumor foci, and prominent pilomyxoid features. [4] For pediatric DIPG and nonbrainstem glioblastoma, two separate studies conducted in 2012, identified the somatic mutations of histone genes, H3F3A (75%) and HIST1H3B (20%-25%) encoding histone H3 variants H3.3 and H3.1, respectively. H3.3 and H3.1 mutations occur in a mutually exclusive manner. [5] Majority of DIPGs and thalamic glioblastoma showed recurrent lysine to methionine substitution at codon 27 (K27M) in one of the two histone H3 variants. [6] A recurrent glycine to arginine/valine substitution at codon 34 was identified in pediatric nonmidline glioblastomas arising from the cerebral hemispheres. [6] The presence of this distinct H3-K27M mutation imparts clinically aggressive behavior and worse prognosis regardless of the histological grade of the tumor and gives reason to keep it as Grade IV tumor by 2016 WHO. Almost ~30% of DIPGs show activating missense somatic mutations in ACVR1 G328 that are concurrent with HIST1H3B K27M mutation. [7] Some important mutation associations of these tumors [2, 8] are summarized in Tables 3 and 4. Multivariate analysis by Castel et al. [9] showed various prognostic factors such as ACVR1 mutation, histone H3 wildtype/K27M status, clinicoradiological risk score, metastasis, and MRI contrast enhancement, but the strongest predictor of survival was mutated histone H3.
These tumors can neither be completely removed surgically due to their location nor be treated effectively with radiotherapy or chemotherapy. In 2017, Piunti et al. [10] found significant suppression of tumor growth in DIPG patients treated with the epigenetic modifier, JQ1, a bromodomain, and terminal family protein inhibitor. Other new epigenetic strategies have been developed targeting chromatin-modifying enzymes. In addition, in some cases, nanotechnology has proven effective. [11] The recognition of this morphologically and molecularly defined tumors accounts for specific therapy against these mutations and their prognosis [ Figure 4 ]. [8] 
ConClusion
The case highlights the importance of exploring for signature mutations in well-defined tumor categories like H3-K27M-mutant diffuse midline gliomas. Phenotypically similar tumors may be genetically heterogeneous and, therefore, have different biological behavior entities. [8] and Hawkins et al. [2] 
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